239 related articles for article (PubMed ID: 25592767)
1. Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.
Chopra M; Bohlander SK
Cancer Genet; 2015 May; 208(5):192-205. PubMed ID: 25592767
[TBL] [Abstract][Full Text] [Related]
2. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
5. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
[TBL] [Abstract][Full Text] [Related]
6. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
[TBL] [Abstract][Full Text] [Related]
7. The role of DOT1L in the maintenance of leukemia gene expression.
Wang X; Chen CW; Armstrong SA
Curr Opin Genet Dev; 2016 Feb; 36():68-72. PubMed ID: 27151433
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
9. New lysine methyltransferase drug targets in cancer.
Wagner T; Jung M
Nat Biotechnol; 2012 Jul; 30(7):622-3. PubMed ID: 22781684
[No Abstract] [Full Text] [Related]
10. Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells.
Valente S; Lepore I; Dell'Aversana C; Tardugno M; Castellano S; Sbardella G; Tomassi S; Di Maro S; Novellino E; Di Santo R; Costi R; Altucci L; Mai A
Biochimie; 2012 Nov; 94(11):2308-13. PubMed ID: 22709867
[TBL] [Abstract][Full Text] [Related]
11. Role of somatic cancer mutations in human protein lysine methyltransferases.
Kudithipudi S; Jeltsch A
Biochim Biophys Acta; 2014 Dec; 1846(2):366-79. PubMed ID: 25123655
[TBL] [Abstract][Full Text] [Related]
12. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
13. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
14. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
[TBL] [Abstract][Full Text] [Related]
16. MLL translocations, histone modifications and leukaemia stem-cell development.
Krivtsov AV; Armstrong SA
Nat Rev Cancer; 2007 Nov; 7(11):823-33. PubMed ID: 17957188
[TBL] [Abstract][Full Text] [Related]
17. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
18. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
19. Targeting Histone Methylation in Cancer.
McCabe MT; Mohammad HP; Barbash O; Kruger RG
Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
[TBL] [Abstract][Full Text] [Related]
20. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
Chang MJ; Wu H; Achille NJ; Reisenauer MR; Chou CW; Zeleznik-Le NJ; Hemenway CS; Zhang W
Cancer Res; 2010 Dec; 70(24):10234-42. PubMed ID: 21159644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]